Natera on Tuesday highlighted the recent publication of CIRCULATE data in Nature, demonstrating the value of minimal residual disease testing to guide chemotherapy in CRC stage 2-3 patients, SVB Securities analyst Puneet Souda tells investors in a research note. The analyst, who made no change to the firm’s Outperform rating, expects the results to support NCCN guideline inclusion of MRD, which is expected to drive commercial payer coverage and community oncology adoption of Signatera, bolstering Natera’s lead in the $20B MRD market.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- Natera’s CIRCULATE data looks strong, says Piper Sandler
- Natera announces publication of new study on ability of Signatera test
- Here’s why Natera is jumping in afternoon trading
- ACMG recommends 22Q screening, Natera runs micro deletion, says Piper Sandler
- ACMG publishes new guideline recommending NIPS for all pregnant individuals
